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Delivery of Antisense Oligonucleotides Using Cholesterol-Modified
Sense Dendrimers and Cationic Lipids
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Cholesterol modified mono-, di-, and tetrameric oligonucleotides were synthesized and hybridized with
antisense oligonucleotides to study their incorporation in cationic liposomes together with the influence
of this dendrimeric delivery system on biological activity. Electrostatic interactions seem to play the
most important role during complexation with cationic lipids. This oligonucleotide formulation gives
a small but significant increase in the inhibition of P-glycoprotein expression in a cellular system.
INTRODUCTION
Antisense oligonucleotides are very powerful tools for
inhibition of gene expression (1). The initial hurdles of
enzymatic instability and poor hybridization strength of
natural antisense oligonucleotides have been largely
overcome by introducing chemical modifications. Delivery
of oligonucleotides to target cells in vivo, however, is the
major bottleneck for the widespread use of antisense
oligonucleotides in therapy (2).
One of the potential solutions for this delivery problem
is the use of liposomes (3). The antisense oligonucleotide
(negatively charged due to the ionization of the phosphate
backbone) interacts electrostatically with the cationic
phospholipids forming the vesicles and is delivered to the
cell by endocytosis. However, the number of oligonucle-
otides trapped into one complex is low. The delivery
process can be improved by conjugation of the antisense
oligonucleotide with cholesterol (4) or by the use of
cholesterol for liposome formulations (5). A disadvantage
of the first approach is that the cholesterol moiety is
covalently attached to the oligonucleotide which influ-
ences the intracellular distribution of the antisense
oligonucleotide.
Despite the efforts that have been made to characterize
the formation of DNA-cationic liposome complexes (lipo-
plexes), the process is not yet completely understood. This
is because multiple factors can influence their formation,
such as the ratio between the number of negative charges
in DNA and that of the positive charges in liposomes,
the fluidity of the lipid bilayer, and the formation of lipid
domains after DNA binding (6). Furthermore, the size
instability was correlated with high transfection ef-
ficiency in vivo (7). The current view about the organiza-
tion of lipoplexes comes from electron microscopy and
X-ray diffraction studies (8, 9). According to these,
lipoplexes have a multilamellar structure with repeat
distances equivalent to the thickness of a lipid bilayer
and a single DNA double helix.
Here we investigated the approach of derivatization
of an enzymatic labile sense-DNA with cholesterol and
delivering the enzymatic stable antisense oligonucleotide
as hybrid with this cholesterol-sense-DNA. As well as
monomers, dimers and tetramers of sense-DNA were
synthesized (Figure 1). Cationic lipids are used for the
liposome formulation. This approach has the advantage
that the enzymatic stable antisense oligonucleotide itself
is not derivatized (i.e. its intracellular distribution and
hybridization with its target is not influenced by a
reporter group). The cholesterol-modified sense-DNA
may stay locked in the endosomes and may be slowly
degraded while the enzymatically more stable antisense
oligonucleotide can diffuse into the cytoplasm and/or the
nucleus (10). The synthesis was tested using an 11-mer
as well as an 18-mer sense-DNA. For biological activity
determination, we selected the 18-mer, as this length
seems to be optimal for this purpose (10). The antisense
oligonucleotide that is used as a model is a phospho-
rothioate 20 gapmer consisting of 2′-methyloxyethyl (2′-
MOE) nucleotides in the flanks and phosphorothioate
DNA in the middle (5′-CCAUCCcgacctcgCGCUCC-3′).
The phosphorothioate DNA gap of eight nucleotides
allows RNaseH to play a role in the mode of action of
the antisense oligonucleotide. The phosphorothioate 2′-
MOE flanks render the oligonucleotide stable against
enzymatic degradation. This sequence has been demon-
strated to inhibit P-glycoprotein expression in a cellular
system (11).
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EXPERIMENTAL PROCEDURES
Chemistry. 1H and 13C NMR spectra were recorded
at 200 MHz with a Varian Gemini 200 in CDCl3. 13C
assignments were based on the usual shift increments
and calculus values and where necessary confirmed by
APT experiments. Assignments of quaternary carbons of
the aromatic rings were based on comparison with other
compounds and were mostly tentative. Electron impact
mass spectra in positive (EI+) and negative ion mode
(EI-) were acquired on a Kratos MS50TC mass spec-
trometer (Kratos, Manchester, UK), using MASPEC II
data acquisition software (Mass Spectrometry Services
Ltd., Manchester, UK). Electrospray ionization mass
spectra in negative ion mode (ESI-) were recorded on a
quadruple orthogonal acceleration/time-of-flight mass
spectrometer (Q-TOf-2, Micromass, Manchester, UK).
Absorption spectra were recorded with a Perkin-Elmer
Lambda 40 spectrophotometer (Wellesley, MA) and fluo-
rescence spectra with a Spex Fluorolog 3-22 fluorimeter
(Jobin Yvon-Spex Instruments S. A., Inc., Edison, NJ).
Precoated Machery-Nagel Alugram SilG/UV 254 plates
were used for TLC, and spots were examined with UV
light and a sulfuric acid/anisaldehyde spray. Column
chromatography was performed on Acros silica gel (60-
200 nm). Anhydrous solvents were obtained as follows:
THF was refluxed on LiAlH4 overnight and was distilled;
dichloromethane (DCM) was stored on calcium hydride,
refluxed, and distilled; pyridine, triethylamine (TEA),
and N,N-diisopropylethylamine (DIEA) were refluxed
overnight on potassium hydroxide and distilled. N,N-
Dimethylformamide (DMF) was stored on activated mo-
lecular sieves (4 Å) for 3 days and was tested for absence
of dimethylamine by the bromophenol test prior to use.
DCM, DMF, acetic anhydride (Ac2O), and pyridine were
obtained from BDH (Poole, England). Piperidine, trifluo-
roacetic acid (TFA), diisopropylcarbodiimide (DIC), 1-hy-
droxybenzotriazole (HOBt), 1-methylimidazole (NMI), di-
tert-butyl dicarbonate [(Boc)2O], benzyl chloroformate,
9-fluorenylmethyloxycarbonyl chloride (FmocCl), 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), and N-methylmor-
pholine were supplied by ACROS (Geel, Belgium). 1-Hy-
droxy-7-azabenzotriazole (HOAt) and its tetramethyl-
uronium derivative (HATU) were purchased from Per-
spective Biosystems. [2-(1H-bentotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate] (HBTU) from
Advanced Chemtech. Benzotriazol-1-yloxytrispyrrolidi-
nophosphonium hexafluorophosphate (PyBOP) was ob-
tained from Advanced Chemtech. Diethyl azodicarbox-
ylate (DEAD) and sodium hydride (NaH) were purchased
from Sigma-Aldrich. p-[(R,S)-R-[1-(9H-fluoren-9-yl)meth-
oxyformamido]-2,4-dimethoxybenzyl]phenoxyacetic acid
(Fmoc-Rink linker) was supplied by Novabiochem. Lipo-
fectamine 2000 was obtained from Invitrogen. PBS buffer
(pH7.4) was obtained from Sigma. Oligonucleotide as-
sembly was performed on an Expedite DNA synthesizer
(Applied Biosystems) using phosphoramidites from Glen
Research.
The 11 and the 18 oligonucleotide sense sequences
without cholesterol, as well as the tetramethyl rhodamine
(TMR)-labeled oligonucleotide antisense sequence, comple-
mentary to the gene encoding the P-glycoprotein (11),
were obtained from Invitrogen. The phosphorothioate
oligonucleotide from Figure 2 is a gift from ISIS.
Cholesterylacetaldehyde Diethylacetal (2). To a
solution of cholesterol (5 g, 12.9 mmol, 1 equiv) in a
mixture of anhydrous THF/DMF (1:1, 200 mL) were
added NaH (3.2 g, 77.6 mmol, 6 equiv) and, after 5 min,
bromoacetaldehyde diethylacetal (6.3 mL, 38.8 mmol, 3
Figure 1. Schematic representation of monomeric and dendrimeric oligonucleotides (DNA) that were used to concentrate antisense
oligonucleotides in cationic lipids for cellular delivery (as well, 11-mer as 18-mer oligonucleotides were evaluated as complexing
agents for the antisense oligonucleotides).
Figure 2. Structure of antisense oligonucleotide directed at mRNA that codes for the P-glycoprotein.
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equiv) under anhydrous conditions. A nitrogen-flushed
reflux condensor was attached, and the mixture was
heated at reflux for 18 h. The excess NaH was decom-
posed using MeOH/CH2Cl2 and mild shaking After
evaporation to dryness, silica gel-based chromatographic
purification was performed with a stepwise gradient of
a hexane/EtOAc mixture (98:2 to 95:5) as eluent, yielding
4.3 g (8.56 mmol, 66.3%) of the title compound. 13C
NMR: δ ) 140.97 (C-3), 121.58 (C-4), 101.46 (â-CH),
79.73 (C-1), 68.77 (R-CH2), 62.09 (Et, CH2O), 56.72 (C-
7), 56.12 (C-10), 50.11 (C-14), 42.25 (C-11), 39.73; 39.45;
38.97 (C-2; C-12; C-24), 37.15 (C-16), 36.78 (C-15), 36.12
(C-22), 35.72 (C-20), 31.84 (C-5, C-6), 28.26; 28.13; 27.92
(C-17; C-9; C-25), 24.19; 23.73 (C-8; C-23), 22.73; 22.46
(C-26; C-27), 20.97 (C-13), 19.27 (C-18), 18.60 (C-21),
15.27 (Et, CH3), 11.75 (C-19). Mass calcd for [M + Cl]-
C33H58O3Cl1: 537.4074, found: (ESI-): 537.4094.
Cholesterylacetaldehyde (3). To a solution of 2 (4.1
g, 8.17 mmol) in CH2Cl2 (80 mL) was added 20 mL of
TFA/H2O (1:1), and the reaction mixture was stirred for
4.5 h at room temperature (complete conversion). NaOH
(1 N) was used to neutralize the solution, and subse-
quently an extraction with CH2Cl2 was performed. The
organic layer was dried over anhydrous MgSO4, filtered,
and evaporated in vacuo to dryness, yielding 3.45 g (8.07
mmol, 98%) of the title compound. 13C NMR: δ ) 201.70
(â-CH), 140.30 (C-3), 122.22 (C-4), 80.37 (C-1), 73.81 (R-
CH2), 56.69 (C-7), 56.12 (C-10), 50.08 (C-14), 42.25 (C-
11), 39.70; 39.42; 38.76 (C-2; C-12; C-24), 36.97 (C-16),
36.72 (C-15), 36.12 (C-22), 35.69 (C-20), 31.81 (C-5, C-6),
28.10; 27.92 (C-17; C-9; C-25), 24.19; 23.73 (C-8; C-23),
22.70; 22.46 (C-26; C-27), 20.97 (C-13), 19.24 (C-18), 18.60
(C-21), 11.75 (C-19). Mass calcd for [M]+ C29H48O2:
428.3654, found (EI+): 428.3647.
Cholesterylacetic Acid (4). Compound 3 (3 g, 7.0
mmol) was dissolved in acetone (105 mL), and 1.5 mL
Jones reagent (26.72 g CrO3/23 mL concentrated H2SO4/
H2O to 100 mL) was added dropwise while the reaction
mixture was cooled on ice. If necessary (TLC), more Jones
reagent was added to completely convert 3 into its
carboxylic acid. After 10 min, acetone and MeOH were
added, the mixture was filtered, and the remaining
filtrate was evaporated to dryness. The residual solid was
purified by column chromatography on silica gel by
elution with hexane/EtOAc/AcOH (8:2:0.1), yielding 2.1
g (4.76 mmol; 68%) of the title compound. 13C NMR: δ )
173.54 (COOH), 140.00 (C-3), 122.46 (C-4), 80.46 (C-1),
65.16 (R-CH2), 56.69 (C-7), 56.12 (C-10), 50.05 (C-14),
42.25 (C-11), 39.67; 39.45; 38.61 (C-2; C-12; C-24), 36.90
(C-16), 36.69 (C-15), 36.12 (C-22), 35.69 (C-20), 31.78 (C-
5, C-6), 28.13; 28.01; 27.92 (C-17; C-9; C-25), 24.19; 23.73
(C-8; C-23), 22.73; 22.46 (C-26; C-27), 20.97 (C-13), 19.24
(C-18), 18.60 (C-21), 11.75 (C-19). Mass calcd for [M]+
C29H48O3: 444.3603, found (EI-): 444.3606.
Nr-Fmoc-NE-cholesterylacetyl-lysine-O-Me (5).
Compound 4 (1.7 g, 3.7 mmol, 1 equiv) and HATU (1.35
g, 4.07 mmol, 1.1 equiv) were suspended in 85 mL of dry
DMF. To this suspension was added DIEA (1.3 mL, 7.4
mmol, 2 equiv), and the resulting solution was stirred
for 2 h at room temperature. To this mixture was added
a solution of Fmoc-Lysine-OMe.HCl (1.7 g, 4.07 mmol,
1.1 equiv) and DIEA (1.3 mL, 7.4 mmol, 2 equiv) in 15
mL of dry DMF, and stirring was continued at room
temperature for 18 h. After evaporation, the residue was
dissolved in EtOAc, and the organic phase was washed
with HCl (1 N), water, saturated Na2CO3 solution, brine,
and water. The organic layer was dried over sodium
sulfate, filtered, and evaporated. The remaining oil was
purified by chromatography using a mixture of CH2Cl2/
MeOH (99:1) as eluent. Evaporation of the pooled frac-
tions yielded 2.5 g (3.1 mmol, 84%) of compound 5. 13C
NMR: δ ) 172.66 (Lys, COOMe), 170.41 (CONH); 156.51
(OCONH), 144.04 (Fmoc, C-10/11), 141.73 (Fmoc, C-12/
13), 140.12 (Chol, C-3), 127.68 (Fmoc, C-3/6), 127.04
(Fmoc, C-2/7), 125.07 (Fmoc, C-1/8), 122.28 (Chol, C-4),
119.97 (Fmoc, C-4/5), 80.39 (Chol, C-1), 67.47 (Fmoc,
CH2O), 66.52 (Chol, R-CH2), 56.66 (Chol, C-7), 56.08
(Chol, C-10), 52.38 (Lys, CH3O), 51.14 (Lys, R-CH) 50.01
(Chol, C-14), 47.22 (Fmoc, C-9), 42.24 (Chol, C-11), 40.61
(Lys, ²-CH2NH), 39.67; 39.45; 38.82 (Chol, C-2; C-12;
C-24), 36.93 (Chol, C-16), 36.69 (Chol, C-15), 36.12 (Chol,
C-22), 35.69 (Chol, C-20), 32.26 (â-CH2(Lys)), 31.80 (Chol,
C-5, C-6), 29.62 (δ-CH2(Lys)), 28.13; 28.01; 27.92 (Chol,
C-17; C-9; C-25), 24.19; 23.73 (Chol, C-8; C-23), 22.73;
22.46 (Chol, C-26; C-27), 22.34 (γ-CH2(Lys)) 20.97 (Chol,
C-13), 19.27 (Chol, C-18), 18.63 (Chol, C-21), 11.74 (Chol,
C-19). Mass calcd for [M+ Cl]- C51H72N2O6Cl1: 843.5078,
found: (ESI-): 843.5049.
Nr-Fmoc-NE-cholesterylacetyl-lysine (6). The cleav-
age of the methyl ester was carried as described in the
literature (12). To compound 5 (1.5 g, 1.8 mmol, 1 equiv)
in 20 mL of THF at 0 °C was added 0.2 N LiOH (18 mL,
3.6 mmol, 2 equiv), and the reaction was stirred for 40
min. To the reaction mixture, 50 mL of a biphase of 0.2
N HCl/EtOAc (1:1) was added, aqueous layer was ex-
tracted three times with EtOAc, and the combined
organic layers were dried over MgSO4, filtered, and
evaporated to dryness. The remaining product was puri-
fied by column chromatography on silica gel with a CH2-
Cl2/MeOH mixture (95:5) as eluent, yielding 1.1 g (1.4
mmol, 77%) of the title compound. 13C NMR: δ ) 174.78
(Lys, COOH), 171.14 (CONH); 156.51 (OCONH), 144.01
(Fmoc, C-10/11), 141.37 (Fmoc, C-12/13), 140.06 (Chol,
C-3), 127.71 (Fmoc, C-3/6), 127.07 (Fmoc, C-2/7), 125.10
(Fmoc, C-1/8), 122.31 (Chol, C-4), 120.00 (Fmoc, C-4/5),
80.46 (Chol, C-1), 67.31 (Fmoc, CH2O), 66.52 (Chol,
R-CH2), 56.63 (Chol, C-7), 56.08 (Chol, C-10), 51.47 (Lys,
R-CH) 49.98 (Chol, C-14), 47.19 (Fmoc, C-9), 42.24 (Chol,
C-11), 40.58 (Lys, ²-CH2NH), 39.67; 39.45; 38.82 (Chol,
C-2; C-12; C-24), 36.90 (Chol, C-16), 36.69 (Chol, C-15),
36.12 (Chol, C-22), 35.72 (Chol, C-20), 32.26 (â-CH2(Lys)),
31.80 (Chol, C-5, C-6), 29.62, 29.19 (δ-CH2(Lys)), 28.16;
28.01; 27.92 (Chol, C-17; C-9; C-25), 24.19; 23.76 (Chol,
C-8; C-23), 22.73; 22.46 (Chol, C-26; C-27), 22.34 (γ-CH2-
(Lys)), 20.97 (Chol, C-13), 19.24 (Chol, C-18), 18.63 (Chol,
C-21), 11.74 (Chol, C-19). Mass calcd for [M-H]- C50H69N2
O6: 793.5155, found: (ESI-): 793.5143.
Solid-Phase Synthesis. Peptide Synthesis. Syn-
thesis of the conjugates was performed on the LCAA-CPG
carrier. For each amino acid or compound to be coupled,
different reaction conditions were applied. After every
reaction, the solution was filtered and the beads were
washed with DMF (two times), CH2Cl2 (2 times), and
acetonitrile (two times). The beads were dried, and Fmoc-
or MMTr- substitution levels were determined. Hereto,
an accurately measured quantity of resin was suspended
in exactly 25 mL of 20% piperidine in DMF or in a HClO4/
EtOH mixture (3:2), respectively. After 15 min the
absorbance was measured at 300 nm for fulvene (or
adduct) determination and at 475 nm for methoxytrityl
cation detection (²Fmoc ) 7500, ²MMTr ) 55000). If the
coupling yields were unsatisfactory, a second coupling
reaction was performed. Before each new coupling, the
remaining amino groups were capped using 1.5 mL of
20% acetic anhydride in THF and 1.5 mL of 20%
1-methylimidazole and 40% 2,4,6-trimethylpyridine in
THF for 15 min, and washed with acetonitrile and DMF.
Fmoc-deprotection was carried out with a piperidine/
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DMF mixture (2:8 v:v, 2 mL) for 5 min and washing for
15 min, while for MMTr-deprotection, 3% TCA in CH2-
Cl2 was used 3 to 4 times for 3 min, until no yellow color
was detectable.
Coupling of Fmoc-sarcosine to LCAA-CPG was gener-
ally performed as described in the literature (13). To a
solution of Fmoc-sarcosine (116 mg, 0.37 mmol, 4 equiv),
HOBt (31 mg, 2.23 mmol, 2.5 equiv), and HBTU (88 mg,
0.23 mmol, 2.5 equiv) in 2 mL DMF was added DIEA
(78 µL, 0.46 mmol, 5 equiv), and the mixture was shaken
for 5 min. More DIEA (78 µL, 0.46 mmol, 5 equiv) was
added, and the solution was then poured onto LCAA-CPG
beads (1 g, 92 µmol, 1 equiv). The reaction mixture was
occasionally shaken for 2 h. Coupling of MMTr-butyric
acid was obtained by adding a solution of 4-OMMTr-
butyric acid (14) (220 mg, 0.46 mmol, 5 equiv), HOBT/
HBTU (88 mg, 0.23 mmol, 2.5 equiv), and DIEA (158 µL,
0.92 mmol, 10 equiv) in 2 mL of DMF. Following
deprotection of MMTr, Fmoc-glycine was coupled to the
4-OH group of 4-OH-butyric acid by occasionally swirling
the beads with a reaction mixture of Fmoc-glycine (273
mg, 0.92 mmol, 10 equiv), DIC (72 µL, 0.46 mmol, 5
equiv), and DMAP (17 mg, 13.8 µmol, 0.15 equiv) in DMF
(2 mL).
The cholesterylacetamide 6 was attached to glycine by
using a solution of 6 (0.29 mg, 0.37 mmol, 4 equiv), HBTU
(140 mg, 0.37 mmol, 4 equiv), HOBt (49 mg, 0.37 mmol,
4 equiv), and DIEA (168 µL, 0.92 mmol, 10 equiv) in 1
mL of DMF. The mixture was shaken for 5 min before it
was added to the Fmoc-deprotected support (yield: 90%).
For single oligonucleotide loading, 4-O-MMTr-butyric
acid was coupled as a linker before starting oligonucleo-
tide synthesis. For the branching-off purposes, NR-Fmoc-
N²-Fmoc-lysine (4 equiv) was used. The protected lysine
was attached to the support by adding a solution of
HBTU (4 equiv), HOBt (4 equiv), and DIEA (10 equiv)
in DMF. Subsequently, 4-O-MMTr-butyric acid was
coupled. The amount of 4-O-MMTr-butyric acid used was
always 4 times the amount of free NH2 groups available
for coupling.
Oligonucleotide Synthesis. Four different supports
were used for assembly of the undeca- and octadecamers.
The number of hydroxyl groups per gram of support was
determined by detritylation and amounted to 48, 80, and
130 µmol/g for the supports 9, 11, 13, respectively. The
assembly of oligonucleotides was done on the Expedite
following a standard 1 µmol protocol, using only 0.5 µmol
of support and a 4 min coupling time. Following depro-
tection with AMA (methylamine-ammonia 1:1) for 2 h
at 25 °C, the products were purified by gel filtration using
30% aqueous acetonitrile to avoid adsorption of the
cholesteryl moieties to the support. Depending whether
a single, double, or four chains of oligonucleotides needed
to be coupled to the cholesterol moiety, one of the
different supports 9, 11, 13 were used. The conjugates
could be purified by RP-HPLC on PLRP-S (100 Å, 8 µM,
250 × 7 mm, Polymer Laboratories) with a CH3CN
gradient in 0.05 M ammonium acetate, pH 7.0. In
general, in ascending order, tetrameric oligo-containing
dendrimer eluted before the trimer, dimer, and monomer
species. Analysis was accomplished by HPLC/MS on a
capillary chromatograph (CapLC, Waters, Milford, CA).
Columns of 150 mm × 0.3 mm length (LCPackings, San
Francisco, CA) were used. Oligonucleotides were eluted
with a triethylammonium-1,1,1,3,3,3-hexafluoro-2-pro-
panol:acetonitrile solvent system, and the flow rate was
5 µL/min. Electrospray spectra were acquired on a
quadrupole orthogonal acceleration/time-of-flight mass
spectrometer (Q-Tof-2, Micromass, Manchester, U.K.) in
negative ion mode. The scan time used was 2 s. The
combined spectra from a chromatographic peak were
deconvoluted using the MaxEnt algorithm of the software
Masslynx 3.4 (Micromass). Theoretical oligonucleotide
masses were calculated using the monoisotopic element
masses for masses up to 8000 and using the average
element masses for masses above 8000. The data are
given in Table 1.
Fluorescence Resonance Energy Transfer (FRET)
Measurements. Lipofectamine 2000 was diluted in PBS
(phosphate buffer saline, pH ) 7.4) (Sigma) and was
labeled with a perylene monoimide derivative (PMI-
COOH) (Figure 3) in an approximate ratio of 1 fluores-
cent molecule for 250 lipid molecules. Hybridization
between the antisense oligonucleotide labeled with TMR
and the DNA with or without cholesterol was performed
by heating appropriate amounts in PBS at 80° for 3 min,
followed by cooling at room temperature for 15 min.
Hybridized DNA was added in increasing concentrations
to the Lipofectamine suspension. The fluorescence energy
transfer between PMI-COOH and TMR was monitored
by exciting the sample at 450 nm (where the direct
excitation of TMR is minimal) and measuring the fluo-
rescence quenching of PMI-COOH at the maximum
emission peak (549 nm). The values were corrected for
the nonlabeled DNA quenching of PMI-COOH fluores-
cence and for the TMR emission at 549 nm.
Cells.NIH 3T3 cells stably transfected with a plasmid
containing the human mdr1 gene (pSK1 MDR) were gift
from M. M. Gottesman. The MDR-3T3 cells were grown
in DMEM (Dulbecco minimal cututred media) medium
containing 10% FBS (fetal bovine serum) and 60 mg/mL
colchicine.
Treatment of Cells with Antisense Oligonucleo-
tides. The experimental protocols were similar to those
previously described (11). Briefly, MDR 3T3 cells were
grown in 162 mm flasks to 95% confluency and then
seeded onto six-well plates at 3 × 105/well in 10% FBS/
DMEM and incubated 24 h. The cells were washed twice
with PBS. Complexes between dendrimers and antisense
Table 1. Results of Mass Spectrometry Analysis of the
Monomeric (10), Dimeric (12), and Tetrameric (14)
Constructs
a series b series
calcd foundc calcd foundc
monomer 6433.4a 6432.8 4226.1a 4225.8
dimer 12358.4b 12356.4 7937.8a 7937.2
tetramer 24202.6b NDd 15368.9b 15367.0
a Monoisotopic mass. b Average mass. c Mass obtained after
deconvolution of the electrospray spectrum. d ND: not determined.
Figure 3. Structure of the perylene monoimide derivative used
as a membrane probe.
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strand were prepared in 10 mM TRIS, 50 mM NaCI, 1
mM EDTA by heating the solutions at 80 °C and cooling
to room temperature for 15 min. The complexation of the
double stranded dendrimeric form of the antisense was
done with Lipofectamine 2000 (Invitrogene) in OptiMEM
according to standard procedure. The complexes were
added to cells in 10% FBS/DMEM. The cells were
incubated with complexes for 4 h. Then the cells were
rinsed and further incubated for 68 h in 2% FBS/DMEM.
All conditions were performed in triplicate. The P-
glycoprotein percent shift is calculated from the lipo-
fectamine 2000 control shift.
Pharmacological Effects of Antisense Treatment.
Analysis of the pharmacological effects of dendrimeric
delivery was based on a previously described assay (15)
involving antisense inhibition of P-glycoprotein expres-
sion in mouse 3T3 cells stably transfected with the
human MDR1 gene. The cell surface expression of
P-glycoprotein was determined by immunostaining and
quantitation by flow cytometry, as described (16). Briefly,
the MRK16 anti-P-glycoprotein antibody (Kamiya Bio-
chemicals), which is directed against an external epitope,
was employed as the primary antibody. After the incuba-
tion, the cells were washed twice in 10% FBS/PBS. The
level of phycoerythrin (PE)-conjugated goat anti-mouse
IgG (Sigma, St. Louis, MO was used as the second
antibody) in viable cells (viability determined by light
scatter) was quantitated using the Summit V3.0 software
application (Cytomation Inc.) on a Becton Dickinson flow
cytometer.
RESULTS AND DISCUSSION
Synthesis. For the synthesis of the monomeric, dimer-
ic, and tetrameric cholesterol oligonucleotide conjugates,
a strategy was used based on lysine chemistry. Lysine
has an R- and ²-amino group, and binding of one lysine
unit via its R carboxyl function to a solid support allows
the two functional amino groups to be used for oligo-
nucleotide synthesis.
Cholesterol (1) was derivatized at its C-3 hydroxyl
group with a functional group that is stable against acid
and base and that can be used for the formation of an
amide bond (Scheme 1). Reaction of cholesterol with
chloroacetic acid in the presence of NaH gives poor yields.
Therefore, cholesterol was first reacted with the dieth-
ylacetal of bromoacetaldehyde in the presence of NaH in
a mixture of THF/DMF for 18 h at 85 °C. In this way
cholesterylacetaldehyde diethylacetal (2) was obtained in
70% yield. Reaction of 2 with Jones reagent resulted in
the formation of the desired cholesterylacetic acid 4, but
the reaction went to completion only after 24 h, and
multiple side products were formed. To avoid side reac-
tions, the acetal was first hydrolyzed with trifluoroacetic
acid in dichloromethane for 4 h, giving the aldehyde 3.
The oxidation of the aldehyde to the carboxylic acid with
Jones reagent was completed after 10 min, giving a clean
reaction product. The oxidation using hypochlorite was
less effective.
Subsequently, Fmoc-Lysine-OMe was coupled with its
free ²-NH2-group to cholesteryl acetic acid using HATU,
DIEA, and TEA (Scheme 1). Compound 5 was then
deprotected by hydrolyzing the methyl ester with 0.2 N
LiOH in THF/H2O. The carboxylic acid of 6 could then
be used to couple 6 to the solid support 7. This solid
support material was obtained by derivatization of
LCAA-CPG with sarcosine. Subsequently, MMTr-O-bu-
tyric acid was attached to the sarcosine and detritylated
with trifluoroacetic acid. The free hydroxyl group was
used for coupling with Fmoc-glycine with formation of a
base-labile ester bond. After Fmoc deprotection, com-
pound 6 was coupled to the solid support 7 using a
mixture of HBTU, HOBT, and DIEA (Scheme 1). In this
way, a cholesterol-derivatized lysine connected to a solid
support via an ester bond was obtained, as general
support for the synthesis of the desired oligonucleotide
monomers (10a,b) and dendrimers (12a,b and 14a,b).
The synthesis of the cholesteryl-lysyl oligonucleotide
(monomer 10a,b) is shown in Scheme 2. After Fmoc
deprotection of 8, coupling of MMTr-O-butyric acid, and
MMTr deprotection, the solid material 8 was used for
oligonucleotide synthesis with the phosphoramidite ap-
proach. An 11-mer and 18-mer were assembled with a
sequence complementary to the antisense oligonucleotide.
Deprotection using AMA reagent (concentrated aq
ammonia-aq methylamine 1:1) yielded 10a,b. The con-
jugate was concomitantly removed from the solid support
by cleavage of the labile ester group with formation of
the methylamide (with 5% amide formation according to
MS analysis).
Branching of the peptide linker was carried out by
coupling of Fmoc-protected lys-OH on deprotected 8
(Scheme 3). After a second deprotection step and binding
of hydroxybutyric acid, the solid support can be used for
the synthesis of two oligonucleotides on the same cho-
lesteryl derivatized peptide (Scheme 3). Repetition of the
protocol of coupling Fmoc-protected lys-OH, Fmoc depro-
tection, and coupling of hydroxybutyric acid might lead
to an exponential branching of the cholesterol-derivatized
Scheme 1. Synthesis of Cholesterol-Conjugated
Lysine on Solid Supporta
a i: BrCH2CH(OEt)2, NaH, DMF/THF; ii: CF3COOH aqueous
in DCM; iii: CrO3, H2SO4, CH3COCH3, H2O; iv: Fmoc-Lysine-
OMe HCL, HATU, DIEA, DMF; v: LiOH, THF, H2O; vi: HBTU,
HOBT, DIEA, DMF.
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Scheme 2. Synthesis of Cholesterol-Modified Oligonucleotide Monomersa
a i: piperidine, DMF; ii: MMTrO(CH2)3COOH, HOBt, HBTU, DIEA, DMF; iii: CCl3COOH, DCM; iv: oligonucleotide synthesis;
v: deprotection (aq. CH3NH2-NH3) 10b: same molecule with oligo sequence: AGGTCGGGATG-.
Scheme 3. Synthesis of Cholesterol-Modified Oligonucleotide Dimersa
a i: piperidine, DMF; ii: (Fmoc)2lys-OH, HBTU, HOBT, DIEA, DMF; iii: MMTrO(CH2)3COOH, HOBT, HBTU, DIEA, DMF; iv:
CCl3COOH, DCM; v: oligonucleotide synthesis; vi: deprotection (aq. CH3NH2-NH3) 12b: same construct with oligo sequence:
AGGTCGGGATG-.
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solid support, enabling the assembly of multiple oligo-
nucleotides on one cholesterol moiety. This is demon-
strated with the branched dendrimer 14a,b in Scheme
4. However, mass spectral analysis of the major fraction
shows that only three of the four hydroxybutyryl moieties
are used for oligonucleotide synthesis. The HPLC sample
of the trimeric compound shows only a small fraction of
the four-branched dendrimer. The three-branched mol-
ecule has an acetylated lysine moiety (although it is not
clear if acetylation has occurred at the R-N or the ²-N of
lysine). Apparently, steric hindrance or the occurrence
of a side reaction hampers the formation of the four-
branched construct. We were able, however, to isolate
sufficient amounts of the tetrameric construct by chro-
matographic purification to carry out biological tests.
Using these three different supports, cholesterol oli-
gonucleotide complexes were formed in a ratio of 1:1
(10a,b), 1:2 (12a,b), and 1:4 (14a,b), and the obtained
products were used for hybridization with the antisense
oligonucleotide followed by cationic liposome complex-
ation. Although it is difficult to analyze the way the
antisense oligonucleotides are associated to the sense-
dendrimers, the stability of the complex was determined
using melting experiments. In all cases, the melting point
was above 70 °C, demonstrating that stable complexes
are formed.
Lipoplexes Formation Followed by FRET. The
dynamics of DNA-liposomes interaction can be moni-
tored in a FRET experiment due to the sixth power
dependence of the fluorescence energy transfer efficiency
to the distance between donor and acceptor. The process
can thus take place on distances of a few nanometers,
meaning that only the DNA bound to the surface of
liposomes will contribute to the variation of the measured
signal. The FRET approach was used to investigate the
association between DNA and liposomes with different
compositions (17), to follow in time the changes in lipid-
DNA interaction during lipoplex formation (18), or to
monitor the oligonucleotide release into living cells (19).
Theoretical calculations of FRET efficiency particularly
applied for the geometry of lipoplexes were also developed
(20).
In the context of our ongoing study of perylene mono-
imide derivatives in biological systems, this type of
fluorescent molecule has been used in these experiments
for several reasons. Due to its hydrophobic rylene core,
the molecule is rapidly incorporated into a lipid bilayer,
while the hydrophilic carboxylic group most probably
anchors the molecule at the phospholipid-water inter-
face. This dye was chosen instead of other fluorescent
probes for membranes (e.g. diphenyl hexatriene DPH or
its derivatives) because of the very high fluorescence
quantum yield (almost 1) and the high photostability in
hydrophobic environments of the PMI chromophore (21),
making possible the detection of fluorescence intensity
variations at very low concentrations (10-8-10-7M). The
molecule is practically devoid of fluorescence in water,
so the dye that was not incorporated into liposomes does
not contribute to the total intensity measured (ongoing
study). In addition, the carboxylic group is negatively
charged at the pH used for these experiments (pH 7.4),
which makes the interaction with the positively charged
lipids composing the Lipofectamine more efficient when
compared to an indocarbocyanine dye with two long alkyl
chains (DiI-C18) (data not shown). Third, the high
spectral overlap between the PMI-COOH emission and
TMR absorption (Figure 4) makes this dye pair very good
for FRET measurements.
Scheme 4. Synthesis of Cholesterol-Modified Oligonucleotide Tetramersa
a i: piperidine, DMF; ii: (Fmoc)2lys-OH, HBTU, HOBT, DIEA, DMF; iii: MMTrO(CH2)3COOH, HOBT/HBTU, DIEA, DMF; iv:
CCl3COOH, DCM; v: oligonucleotide synthesis; vi: deprotection procedure (aq. CH3NH2-NH3). 14b: same construct with oligo
sequence: AGGTCGGGATG.
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The purpose of our experiments was to observe if
cationic liposomes (Lipofectamine) are able to complex
more antisense DNA hybridized with the cholesterol-
modified sense sequence than the same DNA hybridized
with the normal sense oligonucleotide (10). Lipofectamine
suspension labeled with the donor (PMI-COOH) was kept
at constant concentration in all experiments, while
increasing acceptor concentrations (hybridized TMR-
DNA) were added to the sample. Figure 5a and b show
the averages and the standard deviations obtained from
three independent experiments for each double strand
type [naked DNA (11 DNA and 18 DNA) and cholesterol-
modified monomeric (10a,b), dimeric (12a,b), and tetra-
meric (14a,b) DNA were evaluated]. The intensity of the
donor in the presence of the acceptor (IDA) was normalized
to the initial intensity of the donor (ID). Using a loga-
rithmic scale, the first data points in each determination
could be linearly fitted, and the values obtained for the
slopes are given in Table 2.
As can be observed, hybridizing the 20-mer sequence
with the cholesterol-modified sense 11-mer oligonucleo-
tides (10b, 12b, 14b) shifts the slopes of the linear fitting
toward higher values when compared to the unmodified
sense sequence. Assuming that each TMR molecule acts
as an independent acceptor even when two (12b) or four
(14b) DNA oligonucleotides are linked in the same
dendrimer, more donor molecules are quenched for the
same DNA amount added to the system when cholesterol-
modified sequences are used. Thus, the antisense oligo-
nucleotide quantity bound to the liposomes is slightly
higher in the case of cholesterol-modified sense oligo-
nucleotides. The differences between the unmodified and
the cholesterol-modified sequence are not very pro-
nounced, but they are statistically significant. On the
other hand, it seems that the number of oligonucleotides
linked to the same cholesterol molecule does not influence
the binding. When the 18-mer sense sequence is used for
hybridization, no differences in the uptake in lipoplexes
can be observed between the cholesterol-modified (10a,
12a, 14a) and the unmodified oligonucleotides. Another
observation is that the slope values obtained for the 11-
and 18-oligonucleotide sequence are not statistically
different. Given the small length change from the 11 to
the 18 sequences, we can conclude that the electrostatic
interaction is the most important factor governing the
formation of lipoplexes, while the much weaker hydro-
phobic interaction due to the presence of cholesterol may
have a role in the case of short DNA sequences.
The fact that we were not able to find significant
differences in the liposome loading does not necessarily
mean that a higher transfection efficiency in living cells
cannot be obtained with the cholesterol-modified se-
quences. Previous studies reported a higher transfection
efficiency obtained with cholesterol-modified oligonucleo-
tides by themselves due to an increased binding to the
cellular membranes (23, 24). It seems thus possible that
the uptake and the metabolization pathways, even when
using a delivery agent, are different for the cholesterol-
modified sequences when compared to the usual ones.
Biological Activity. The biological activity was de-
termined using the 2′-MOE gapmer of phosphorothioate
as the antisense strand (Table 3). The concentration was
determined spectroscopically. When incubating the anti-
sense oligonucleotide with Lipofectamine 2000, a maxi-
mum activity was obtained at 50 nM (giving 42.2% P-gp
shift). Therefore, this antisense concentration was used
in further experiments. When the cholesterol dendrimers
Figure 4. Absorption and emission spectra for PMI-COOH and
TMR. The filled area represents the overlap between the
emission spectrum of PMI-COOH and the absorption spectrum
of TMR. The overlap integral calculated according to the Fo¨rster
relation (22) is J ) 5.2 × 10-13 cm6 mmol-1 and the Fo¨rster
radius is ≈60 Å.
Figure 5. Quenching of PMI-COOH fluorescence (labeling Lipofectamine) using the 11 (a) and the 18 (b) oligonucleotide sequence
for hybridization of the TMR-antigene sequence. The intensity of the donor in the presence of the acceptor (IDA) was normalized to
the initial intensity of the donor (ID). Note that logarithmic scale was used. The first data points in each determination could be
linearly fitted, and the values obtained for the slopes are given in Table 2.





11DNA (5.14 ( 0.33) × 106 18DNA (5.68 ( 0.54) × 106
10b (6.37 ( 0.35) × 106 10a (5.85 ( 0.30) × 106
12b (5.70 ( 0.20) × 106 12a (5.94 ( 0.42) × 106
14b (6.15 ( 0.47) × 106 14a (5.82 ( 0.43) × 106
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12a and 14a were tested in complex with the antisense
construct but without adding lipofectamine 2000, no
significant effect was seen except after very long incuba-
tion time (72 h). This means that the dendrimers alone
were not effective in delivering the antisense oligonu-
cleotide. Significant effects were obtained when the
dendrimers 12a and 14a were used in the presence of
lipofectamine 2000 (Table 3). After 48 h incubation the
antisense oligonucleotide gives 62.8% P-gp shift, while
in the presence of the dendrimers and using 1:1, 1:2, or
1:4 molar ratios of dendrimer and antisense oligonucleo-
tides (fixed at 50 nM), the P-gp shift varied from 68.9%
to 74.0%. The effect is modest but significant. The
biological activity is somewhat increased when the anti-
sense oligonucleotides are more condensed (ratio 1:1
versus ratio 1:2 or 1:4).
CONCLUSION
Using a linker based on lysine chemistry, we were able
to synthesize monomeric, dimeric, and tetrameric oligo-
nucleotide constructs covalently linked to a cholesterol
moiety. These monomeric and dendrimeric sense DNA
were complexed with enzymatic stable antisense oligo-
nucleotides targeting P-glycoprotein expression. Perylene
dye was used to monitor uptake of the constructs in
cationic lipids. In the case of 11-mer cholesterol-modified
sense DNA, a higher amount of antisense oligonucleotide
could be incorporated in the cationic liposomes than
without cholesterol modification. However, this difference
did not exist with the 18-mer cholesterol-modified sense
DNA. Also the number of oligonucleotides linked to the
same cholesterol moiety does not influence binding to the
cationic lipids. In this case, electrostatic interactions
seems to play the most important role during complex
formations and longer sense DNA gives higher concen-
tration of antisense DNA in the lipoplexes. The previously
observed results of the better delivery of duplex oligo-
nucleotide versus single-stranded oligonucleotides (10)
may be partially explained by this phenomenon. How-
ever, dendrimer delivery of the antisense oligonucleotide
using cholesterol-modified 18-mer sense DNA and lipo-
fectamine resulted in a small but significant increase in
biological activity. This increase in biological activity is,
most probably, due to a difference in intracellular me-
tabolism i.e., the kinetics with which the antisense
oligonucleotide is delivered to its target mRNA.
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